We are driven by a passion to solve scientific challenges and to realize cell therapy

We are revolutionizing cell culture

BioLamina is a Swedish biotechnology company with a global presence. We offer an expansive portfolio of chemically defined and animal component-free laminin proteins for a variety of applications, including reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types, such as hepatocytes, skeletal muscle cells and different neural cells.

We are known and recognized for our premium products, competence, dedication and service and position ourselves as being in the forefront of cell culturing. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. BioLamina’s Biolaminins™ are the only original full length, human, recombinant laminin cell culture substrates on the market and the impact of our Biolaminin matrices on cell culture quality has been scientifically validated in many high-impact journals. 

BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture based research. The company was established in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 20 employees spanning from production, R&D, logistics, sales and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

 

                                                                                                                                                          MORE INFORMATION ABOUT OUR TECHNOLOGY

          Not getting our newsletter?

          Sign up here

 

          Press images

          BioLamina Newsletters

                        November 2018

                        September 2018

                        May 2018 (3)

                        May 2018 (2)

                        May 2018

                        April 2018

                        January 2018

                        November 2017

                        September 2017

                        May 2017 (2)

                        May 2017 

                        March 2017 (2)

                        March 2017

                        January 2017

                        November 2016 (2)

                        November 2016

                        October 2016

                        June 2016                      

                        May 2016

                        January 2016

                        November 2015

                        June 2015

                        March 2015

                        November 2014          

                        September 2014                        

                        June 2014

                        May 2014

                        January 2014

                        October 2013

                        June 2013

                        May 2013

                        January 2013

                        November 2012

                        October 2012

                        June 2012

                        May 2012

                        March 2012

                        November 2011

                        October 2011 

                        September 2011

                        June 2011

 

Utmanar Car-T

Svenska Biolamina ska utveckla metoder för tillverkning av NK-celler. "Orsakar inte någon immunreaktion".

Life Science Sweden, November 7, 2018


BioLamina and partners aim to develop new methods to differentiate unlimited amounts of NK-cells to fight cancer

Together with Rheincell Therapeutics and the University Clinic in Düsseldorf (Universitätsklinikum Düsseldorf), over the next two years BioLamina will develop methods to differentiate NK cells supported by a grant of 12 MSEK from Swedish Vinnova and German ZIM. BioLamina’s expertise with laminin technologies will be used to differentiate stem cells into NK-cells, which are then further manipulated to form CAR-NKs. The CAR-NKs are predicted to be safer to patients, and potentially even more efficient in treating some forms of cancer than the current “star” of the proverbial cell therapy sky, the CAR-T cell. CAR-T cells have significantly increased the prognosis for cancer patients, with two approved therapies in Europe alone. With success, the stem cell-derived CAR-NKs borne of this collaborative effort could prove to be another game-changer in the field of cancer therapeutics.

BioLamina, Stockholm, Sweden, November 7, 2018


BIOLAMINA announces an OEM partnership with CELLINK for the development of biologically relevant bioink products for bioprinting

During recent years, 3D-Bioprinting has emerged as a powerful cell culture technology but has also been hampered by the lack of a biologically relevant Bioink. Today, CELLINK launches a brand new Bioink containing BIOLAMININS, that will enable scientists to combine the unique properties of the laminin protein with culturing cells in a 3D-enviroment. This approach will advance the 3D-Bioprinting technology since the biological effect of the laminin protein will improve the structure and biochemical features, creating a microenvironment more authentic to the in vivo setting.

BioLamina, Stockholm, Sweden, August 21, 2018


BioLamina takes the next step in their expansion plan and scale up the production at  Testa Centre 

To meet the fast-growing demand from customers both in terms of volume and high-quality products, BioLamina will, together with GE, expand production capacity in the newly built Testa Centre in Uppsala. The newly built innovation center, supported by GE Healthcare and the Swedish Government, offers high-quality bioprocess expertise and will serve as a hub for innovation in biomanufacturing.  

BioLamina, Stockholm, Sweden, August 21, 2018


BioLamina and Novo Nordisk partner to advance stem cell based therapies for three common medical conditions

BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina. The three cell therapy projects they have licensed are all based on BioLamina technology. These projects aim to treat Parkinson’s disease, heart failure and loss of vision, all severe chronic conditions.

BioLamina, Stockholm, Sweden, May 16, 2018


BioLamina launches a cell therapy grade stem cell culture matrix, Biolaminin 521 CTG, bridging discovery and clinical cell therapy

BioLamina is currently undergoing an exciting phase entering the growing cell and gene therapy reagents industry. To meet the growing demand for documentation and traceability required for the manufacture of cells for therapy, BioLamina has launched a cell therapy grade (CTG) laminin substrate for clinical use, Biolaminin 521 CTG.

BioLamina, Stockholm, Sweden, May 2, 2018


Ny topp till Biolamina

Efterfrågan på laminin har ökat senaste året och för att säkerställa fortsatt tillväx inom så väl produktion som logistik har bolaget nu tillsatt Anders Lindblad som ny operativ chef.

Life Science Sweden, April, 2018


BioLamina stärker ledningen för ny fas – tillsätter ny operativ chef

BioLamina är i en expansiv fas med betydande affärsmöjligheter globalt. Under det senaste decenniet har laminin kommit att bli ett efterfrågat cellodlingssubstrat både inom grundforskning såväl som för forskare och företag med terapeutisk inriktning. För att kunna säkerställa fortsatt tillväxt inom produktion, logistik och ekonomi har BioLamina rekryterat en ny operativ chef, Anders Lindblad. Anders har en gedigen bakgrund inom operativ ledning, kvalitetssäkring och regulatoriska frågor inom Life Science. Han kommer närmast från roller som COO/Administratör på Cadila Pharmaceuticals Sweden, samt egen konsult för kvalitet och projektledning inom cellterapi och närliggande områden.

BioLamina, Stockholm, Sweden, April 16, 2018


En produkt som möjliggör nya cellterapier

Drömmen är på väg att bli sann. I maj lanseras BioLamina officiellt en produkt för användning i kliniska prövningar. Den har redan använts för att tillverka ett kliniskt provmaterial som testats på 6 patienter, och flera företag väntar på godkännande för att starta kliniska prövningar.

Forskningssverige, Mars, 2018


BioLamina stärker ledningen med en ny chef för marknadsföring och försäljning

BioLamina’s produkter används idag i många cellterapi-relaterade projekt och efterfrågan och försäljningen ökar kraftigt år efter år. För att möta den ökade efterfrågan har BioLamina rekryterat en ny sälj- och marknadschef, Jenny Stjernberg. Jenny kommer närmast från Miteney Biotec där hon var sälj- och marknadschef för den Nordiska och Baltiska avdelningen och har en gedigen erfarenhet av försäljning och marknadsföring av cellodlingsprodukter.

BioLamina, Stockholm, Sweden, November 29, 2017


BioLamina utlicensierar ett patent mot en miljard kronor i möjliga milestones och royalties

Forskare på Lunds universitet har, med hjälp av BioLaminas produkter, lyckats utveckla ett effektivt sätt att tillverka dopaminceller från stamceller, ett viktigt genombrott i resan mot en cellterapibehandling för personer med Parkinsons sjukdom. BioLamina har nu framgångsrikt hittat en licenstagare till detta projekt bland ett av de stora globala läkemedelsbolagen. 

BioLamina, Stockholm, Sweden, September 14, 2017


Corning introduces laminin-521 cultureware products 

Corning has developed Corning® PureCoat™ rLaminin-521 cultureware products for stem cell research, by combining BioLamina’s expertise in rLaminin-521 expression with Corning’s proprietary surface coating technology.

CORNING, N.Y., Corning Incorporated, April 20, 2016


BioLamina utökar globalt - tecknar flera distributionsavtal

ThermoFisher, Corning, Stem Cell Technologies och ESI-Bio, kommer nu att sälja LN521 som en del av sin cell kultiverings portfölj via sina försäljningskanaler.

BioLamina, Stockholm, February 2, 2016


Liver cell therapies closer as study reveals key to mass production

Stem cell scientists have made a key find that aids the quest to produce therapies for patients with liver damage. They have developed a new technique for growing liver cells from stem cells that is cost-effective and could be adapted for mass production of clinical grade cells.

MRC Centre for Regenerative Medicine, Edinburgh, UK, November 25, 2015


Production of recombinant laminins for ex vivo cell therapies

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies. First commercial CAP(R)Go-derived laminin, LN521, expected to be globally available in 2016. 

Dow Jones Newswire Web, October 28, 2015


BioLamina engages Dr. Stephen Minger as Scientific Advisor

BioLamina’s long-term goal is to provide a portfolio of high quality, easy to use, products and services for primary cell culture within research, drug discovery models and cell therapy. To reach this goal, BioLamina needs to focus on the right products and deliver them with the right quality. Dr. Minger’s role will be to help direct and prioritize this work, to ensure release of quality products in a timely fashion. He will work closely with our scientists and executive management.

BioLamina, Stockholm, Sweden, September 28, 2015


Corning Announces New Agreement with BioLamina

More comprehensive and scalable culture solution made available to Corning’s global customer base.

CORNING, N.Y., September 11, 2014


BioLamina tar täten när stamcellsfältet öppnas

A new method makes it possible to culture large amounts embryonic stem cells without destroying the embryo. This method can give more than 400 kilos of stem cells in a month at the same time as it avoids any ethical issues related to stem cell research.

Life Science Sweden, January, 2014


BioLamina is recruiting three new members

The Stockholm based research company BioLamina is strengthening its position through recruiting three new members: Camilla Myhre Sandberg, Anders Blom och Fredrik Mattsson.

Life Science Sweden, November, 2013 


Laminin article in GEN Biotech

In this article, Dr. Karl Tryggvason discuss the use of biologically relevant human recombinant laminins from BioLamina that successfully recreate specific cell niches in the cell culture dish. This enables robust cell cultivation in highly physiological microenvironments that practically solves all current technical challenges with stem cell culture.

GEN Biotech, May, 2013


BioLamina ranked as one of 24 hottest startups in Sweden

BioLamina listed as the only biotech among Sweden's 24 most promising start-ups in Sweden. 

Veckans Affärer, April 18, 2013


BioLamina listed as Sweden's 33 most successful startups

BioLamina ranked as one of Sweden's 33 hottest technology companies, 3rd year in a row.

NyTeknik, April 16, 2013


BioLamina is a company in constant development and progress, and we truly believe our strength comes from our employees. It is therefore very important for us to find people who share our vision and values, and want to be part of creating the next generation of regenerative therapies.
 
If you are interested in knowing more about us and what being part of the BioLamina team would mean, don’t hesitate to contact us at career@biolamina.com

 

We are hiring:

 

      Join the BioLamina family

 

 

 

 

 

 

 

 

 

 

 

Students

BioLamina is a research-based company and we know and value the knowledge that resides in the young and vital university community. Therefore, we are always open to have a dialogue with students who want and need to get “real life” practice.